{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:24:27Z","timestamp":1792589067156,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Current guidelines for treating vaccine-induced immune thrombotic thrombocytopenia (VITT) recommend nonheparin anticoagulants and IV immunoglobulin (IVIg). However, the efficacy of these treatments remains uncertain due to case studies involving small patient numbers, confounding factors (eg, concurrent treatments), and a lack of animal studies. A recent study proposed danaparoid and heparin as potential VITT therapies because of their ability to disrupt VITT IgG-platelet factor 4 (PF4) binding. Here, we examined the effects of various anticoagulants (including unfractionated [UF] heparin, danaparoid, bivalirudin, fondaparinux, and argatroban), IVIg, and the Fc\u03b3RIIa receptor-blocking antibody, IV.3. Our investigation focused on VITT IgG-PF4 binding, platelet activation, thrombocytopenia, and thrombosis. Danaparoid, at therapeutic doses, was the sole anticoagulant that reduced VITT IgG-PF4 binding, verified by affinity-purified anti-PF4 VITT IgG. Although danaparoid and high-dose UF heparin (10 U\/mL) inhibited platelet activation, none of the anticoagulants significantly affected thrombocytopenia in our VITT animal model and all prolonged bleeding time. IVIg and all anticoagulants except UF heparin protected the VITT mice from thrombosis. Direct Fc\u03b3RIIa receptor inhibition with IV.3 antibody is an effective approach for managing both thrombosis and thrombocytopenia in the VITT mouse model. Our results underscore the necessity of animal model investigations to inform and better guide clinicians on treatment choices. This study provides compelling evidence for the development of Fc\u03b3RIIa receptor blockers to prevent thrombosis in VITT and other Fc\u03b3RIIa-related inflammatory disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013883","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T17:19:38Z","timestamp":1726679978000},"page":"5744-5752","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-3209","authenticated-orcid":false,"given":"Halina H. L.","family":"Leung","sequence":"first","affiliation":[{"name":"1Department of Haematology, St. George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-2105","authenticated-orcid":false,"given":"Brendan","family":"Lee","sequence":"additional","affiliation":[{"name":"2Biological Resources Imaging Laboratory, Mark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Casey","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Townsville University Hospital and Health Service, Townsville, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Ratnasingam","sequence":"additional","affiliation":[{"name":"4Department of Haematology, University Hospital Geelong, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"McKenzie","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-708X","authenticated-orcid":false,"given":"Jose","family":"Perdomo","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia"},{"name":"6Department of Haematology, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-490X","authenticated-orcid":false,"given":"Beng H.","family":"Chong","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia"},{"name":"7Department of Haematology, New South Wales Health Pathology, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"5","key":"2024112216355243800_bib1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3324\/haematol.2021.280366","article-title":"Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy","volume":"107","author":"Greinacher","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"2024112216355243800_bib2","first-page":"2010","article-title":"Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection","volume":"109","author":"Uzun","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"2024112216355243800_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMc2307721","article-title":"Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies","volume":"389","author":"Warkentin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024112216355243800_bib4","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","article-title":"NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Leung","year":"2022","journal-title":"Nat Commun"},{"issue":"22","key":"2024112216355243800_bib5","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024112216355243800_bib6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024112216355243800_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccination","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024112216355243800_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2024112216355243800_bib9","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.2021013839","article-title":"The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia","volume":"139","author":"Singh","year":"2022","journal-title":"Blood"},{"key":"2024112216355243800_bib10","volume-title":"World Health Organization TTS Guideline Development Group","year":"2023"},{"key":"2024112216355243800_bib11","article-title":"Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)","author":"World Health Organization","year":"2021","journal-title":"World Health Organization"},{"issue":"5","key":"2024112216355243800_bib12","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study","volume":"5","author":"Dhakal","year":"2018","journal-title":"Lancet Haematol"},{"issue":"22","key":"2024112216355243800_bib13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024112216355243800_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH08-10-0659","article-title":"Heparin-induced thrombocytopenia: what clinicians need to know","volume":"101","author":"Chong","year":"2009","journal-title":"Thromb Haemost"},{"issue":"17","key":"2024112216355243800_bib15","doi-asserted-by":"crossref","first-page":"e4804","DOI":"10.21769\/BioProtoc.4804","article-title":"Determination of antibody activity by platelet aggregation","volume":"13","author":"Leung","year":"2023","journal-title":"Bio Protoc"},{"issue":"1","key":"2024112216355243800_bib16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","article-title":"Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia","volume":"10","author":"Perdomo","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2024112216355243800_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","article-title":"A\u00a0diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood"},{"issue":"8","key":"2024112216355243800_bib18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","article-title":"Heparin-induced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA","volume":"98","author":"Reilly","year":"2001","journal-title":"Blood"},{"issue":"23","key":"2024112216355243800_bib20","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/bloodadvances.2020003093","article-title":"Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia","volume":"5","author":"Leung","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024112216355243800_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5493\/wjem.v2.i2.30","article-title":"Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice","volume":"2","author":"Liu","year":"2012","journal-title":"World J Exp Med"},{"issue":"18","key":"2024112216355243800_bib22","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024112216355243800_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2023000503","article-title":"Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond","volume":"2023","author":"Greinacher","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2024112216355243800_bib24","first-page":"5","article-title":"A\u00a0systematic review of Cochrane anticoagulation reviews","volume":"11","author":"Cundiff","year":"2009","journal-title":"Medscape J Med"},{"issue":"8","key":"2024112216355243800_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"23","key":"2024112216355243800_bib26","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024112216355243800_bib27","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","article-title":"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia","volume":"106","author":"Althaus","year":"2021","journal-title":"Haematologica"},{"issue":"22","key":"2024112216355243800_bib28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024112216355243800_bib29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.2022016474","article-title":"Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024112216355243800_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024112216355243800_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2133.2008.08700.x","article-title":"Intravenous immunoglobulins induce CD32-mediated platelet aggregation in\u00a0vitro","volume":"159","author":"Pollreisz","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"2024112216355243800_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/vox.12307","article-title":"Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin","volume":"110","author":"Yu","year":"2016","journal-title":"Vox Sang"},{"issue":"2","key":"2024112216355243800_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024112216355243800_bib34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.2021012479","article-title":"The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Uzun","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024112216355243800_bib35","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3324\/haematol.2021.280251","article-title":"The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies","volume":"107","author":"Vayne","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"2024112216355243800_bib36","first-page":"1332","article-title":"Immune thrombosis: exploring the significance of immune complexes and NETosis","volume":"12","author":"Perdomo","year":"2023","journal-title":"Biology (Basel)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5744\/2314866\/blooda_adv-2024-013883-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5744\/2314866\/blooda_adv-2024-013883-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:36:07Z","timestamp":1732275367000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5744\/517890\/Antithrombotic-efficacy-and-bleeding-risks-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":35,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013883","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.21.589853","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}